Antimicrobial activity of Streptomyces griseoviridis K10 against ESBL Escherichia coli, MRSA, and other pathogenic microorganisms

by Isnaeni Isnaeni
Antimicrobial activity of *Streptomyces griseoviridis* K10 against ESBL *Escherichia coli*, MRSA, and other pathogenic microorganisms

M F Warsito¹, Ismaeni² and I Kusumawati²

¹Research Center for Biotechnology, Indonesian Institute of Sciences (LIPI), Komplek CSC-LIPI Jl. Raya Bogor Km 46, Cibinong-Bogor 16911, West Java, Indonesia.
²Faculty of Pharmacy, Airlangga University, Nanizar Zaman Joenoes Building, Jl. Mulyorejo, Surabaya 60155, East Java, Indonesia.

Email: mferdina@gmail.com

**Abstract.** The emergence of resistant pathogenic bacteria is a serious threat to global public health. This problem can be addressed through discovering new antibiotics from nature. *Streptomyces* are known as the source of more than fifty percent commercially available antibiotics, but it is predicted that only less than 5% were identified. *Streptomyces griseoviridis* K10 were fermented in ISP-4 medium pH 7.2 for four days in 32 °C incubated shaker with 150 rpm agitation. The antimicrobial activity of *Streptomyces griseoviridis* K10 were analyzed using diffusion method. The antibiotic production curves were made to determine the optimal antibiotic production time. The result showed that these bacteria had activity against extended-spectrum beta-lactamases (ESBL) *Escherichia coli*, Methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa* ATCC 27853, *Escherichia coli* ATCC 25922, *S. aureus* ATCC 25923, and *Candida albicans*, with inhibitory zone of 17.28 ± 0.43 mm; 13.95 ± 0.60 mm; 20.96 ± 0.41 mm; 20.64 ± 0.92 mm; 21.73 ± 0.53 mm; and 16.90 ± 1.27 mm, respectively. The antibiotic production was optimum in the second and third days.

1. **Introduction**

Antibiotics resistance is a serious threat to global public health [1,2]. Although there is considerable progress in the fields of chemical synthesis and engineered biosynthesis of antimicrobial compounds, most antibiotics are too complex to synthesize [3]. One of the strategies to address such crisis is by discovering and developing new antibiotics from nature.

Microorganisms have been an enormous source of biodiversity and chemical diversity. They have capability to produce highly complex molecules from common nutrients in the fermentation process. They become the main source drugs and often used in the industrial-scale production of drugs[4]. Terrestrial derived microorganisms have been the most important resource for discovery of new drugs, especially actinomycetes. *Streptomyces*, one of actinomycetes member, is well known producer of vast majority antibiotics, but only 1-3% have been discovered [5]. Thus, *Streptomyces* is still a potential source of natural product with anti-infective activity.

*Staphylococcus aureus* and *Escherichia coli* are two of the most common pathogenic bacteria that caused infection [6, 18, 19]. These bacteria have been identified to gain resistance against various antibiotics and have spread around the world, even in the countries that known to have low prevalence such as Norway, Denmark, and Finland [7,8]. Thus, there are urgency to find new antibiotics which had activity against these resistance bacteria.

---

Creative Commons License: This work is licensed under a Creative Commons Attribution 3.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
Streptomyces griseoviridis K10 which had been isolated from kale plant tissue area in Sidurjo were analyzed for its antimicrobial activity against several microorganisms such as extended-spectrum beta-lactamases (ESBL) Escherichia coli, Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922, S. aureus ATCC 25923, and Candida albicans. These study also evaluated the growth curve of the bacteria.

2. Materials and Methods

2.1. Materials
Bacteria that had been used in these study were Streptomyces griseoviridis K10, ESBL E.coli, MRSA, Pseudomonas aeruginosa ATCC 27853, E. coli ATCC 25922, S. aureus ATCC 25923, and Candida albicans.

Materials that had been used in these study were International Streptomyces Project 4(ISP-4) media(Himedia), Nutrient agar (NA) media (Himedia), Sabouraud Dextrose Agar (SDA) (Himedia) and agar bacteriological (Himedia). All other materials were analytical grade.

2.2. Characterization of S. griseoviridis K10
The isolate were cultivated on ISP-4 medium and characterized by following the directan in Bergey's Manual of Systematic Bacteriology [9]. The bacteria characteristics such as the color of aerial mycelium, substrate mycelium and pigmentation of the isolate were observed [10]. The ability of the isolate in the utilization of various carbon sources were evaluated [11]. The isolate also observed for its ability to grow in different pH, salinity, and temperatures.

2.3. S. griseoviridis K10 fermentation
Single isolate of S. griseoviridis K10 were put into 25 mL ISP-4 broth medium and incubated in thermostaker (Gerhardt ) with controlled condition, 32±2°C and agitation of 150 rpm, for two days. 10^8-10^7 cfu bacteria from the pre-culture inoculated into 150 mL ISP-4 broth medium and growth in the same fermentation condition [12]. Each day, every 24 hours, the culture were sampled and analyzed for its antimicrobial activity.

2.4. Determination of S. griseoviridis K10 growth curve
The growth curve of S. griseoviridis K10 were determined using dry weight cell method based on Moreira [13]. Briefly, 5 mL of cultured were sampled every 24 hours, centrifuged in 10,000 rpm, and the pellet were dried in oven in controlled condition at 105 °C until the weight of the cell constant. The determination of dry weight cell were done in five replication.

2.5. Antimicrobial screening
The pathogenic microorganism were growth in NA media for bacteria and SDA for fungi. Bacteria, such as ESBL E.coli, MRSA, Pseudomonas aeruginosa ATCC 27853, E. coli ATCC 25922, and S. aureus ATCC 25923 were grown in NA slant media and incubated in thermally controlled incubator (Memmert) in 32±2 °C for 18 hours. The pathogenic fungi, Candida albicans, were grown in SDA media under the same condition. The pathogenic microorganisms then suspended in 10 mL NaCl 0.9% sterile solution. The transmittance of the suspension were measured using spectrophotometer (UV-Vis Spectrophotometer, Agilent 8453) in 580 nm and diluted until the transmittance reached 25% [14].

12 mL of NA media were used as base layer and 8 mL NA media were inoculated with 8 μL pathogenic microorganism suspension for antimicrobial activity test.

The antimicrobial assay conducted using well diffusion method. 100 μL of 3 days old S. griseoviridis K10 culture supernatant was put into the well of test media containing pathogenic microorganism that had been made using cork borer. The media then incubated in thermally controlled incubator (Memmert) in 32±2 °C for 18 hours. The antimicrobial assay done in five replicate.

2.6. Antimicrobial production curve
The antimicrobial production curve were determined using supernatant of *S. griseoviridis* K10 culture, which were grown in ISP-4 broth medium according to section 2.3 and sampled every 24 hours for four days. The antimicrobial assay were done using ESBL *E.coli* and MRSA as test organisms and the method was described previously in section 2.5.

3. Result and Discussion
The isolate, *S. griseoviridis* K10 (Figure 1), had yellowish pink aerial miselium, light orange yellow substrate miselium, and had melanoid pigment. It can utilize various carbon sources such as amyland, arabinose, dextrose, fructose, galactose, glucose, lactose, lactulose, sarose, and sucrose. The isolate also had ability to grow in temperature between 25 °C to 37 °C, pH range 5 to 9, and 2% salinity of the media. If the salinity was 5% or higher, the isolate were unable to grow.

![Figure 1. S. griseoviridis K10](image)

These study showed that *S. griseoviridis* K10 had broad antimicrobials activities against ESBL *E. coli*, MRSA, *Pseudomonas aeruginosa ATCC 27853*, *E. coli ATCC 25922*, *S. aureus ATCC 25923*, and *Candida albicans* (Table 1).

| Test microorganism               | Inhibition zone (mm) |
|----------------------------------|----------------------|
| **ESBL Escherichia coli**        | 17.25 ± 0.43         |
| MRSA                            | 13.95 ± 0.60         |
| *Pseudomonas aeruginosa ATCC 27853* | 20.96 ± 0.41     |
| *Escherichia coli ATCC 25922*   | 20.64 ± 0.92         |
| *S. aureus ATCC 25923*          | 21.73 ± 0.53         |
| *Candida albicans*              | 16.90 ± 1.27         |

Table 1. Antimicrobial activities of *S. griseoviridis* K10 against pathogenic microorganisms

These finding correlate with the previous study that reported that *S. griseoviridis* had activity against gram positive bacteria, such as *S. aureus*, *Micrococcus luteus*, *Bacillus pumilus*, and *Bacillus subtilis*, and gram negative bacteria, such as *E. coli* and *P. aeruginosa* [15]. It was also reported that these species produce griseoviridin and viridogrisein that exert bactericidal activity which also effective against many multi-drug resistant microorganisms [16], such as vancomycin-resistant *Enterococcus faecium* [17]. Thus, it proved the potency of these isolate to produce antimicrobial substances with broad spectrum activity.

The growth curve and antimicrobial production curve of *S. griseoviridis* K10 were showed in Figure 2. The *S. griseoviridis* K10 had the optimum activity against MRSA, which reach 14.34 ± 0.25 mm, in the second day of fermentation when the growth in the late log phase and ESBL *E. coli*, which reach 17.25 ± 0.43 mm, in the third days of fermentation when the growth in about the stationary
phase. The determination of the bacterial growth phase need to study further with narrower sampling time, to predict the growth phase more accurately.

![Graph showing bacterial growth and inhibition zones]

**Figure 2.** The growth curve and antimicrobial production curve of *Streptomyces griseoviridis* K10

The graph showed that *S. griseoviridis* had two different optimum antibiotic production day, for two different resistance bacteria, it is probably because it can produce several different chemical compound with antimicrobial activity.

4. **Conclusion**

*S. griseoviridis* K10 had broad range antimicrobial activity against both pathogenic fungi and bacteria. It also had activity against resistance bacteria such as MRSA and ESBL. *E. coli*. Thus, they are potential to be studied further.

5. **Acknowledgement**

This research was partly funded by the DIPA BOPTN Universitas Airlangga, based on Decree of Rektor Universitas Airlangga No: 1349/UN3/2014, May 2014.

6. **References**

[1] Nahrgang S, Nolte E, and Rechel B 2018 *Antimicrobial resistance* (Health Policy Series, No. 51) ed Rechel B, Maresso A, Sagan A, Hernández-Quevedo C, Richardson E, Jakubowski E, McKee M, and Nolte E (Copenhagen: European Observatory on Health Systems and Policies) chapter 4 pp 67-74

[2] Aslam B, Wang W, Arshad M I, Khurshid M, Muzammil S, Rasool M H, Nisar M A, Alvi R F, Aslam M A, Qamar M U, Salamat M K F, and Baloch Z 2018 *Infect Drug Resist* 11 1645–1658

[3] da Cunha B R, Fonseca L P and Calado C R C C 2019 *Antibiotics* 8 2

[4] Singh R, Kumar M, Mittal A, and Mehta P K 2017 *3 Biotech* 7 1

[5] Clardy J, Fischbach MA and Walsh CT 2006 *Nature Biotechnology* 24 12

[6] Russo T A and Johnson J R 2003 *Microbes Infect.* 5 5

[7] Chambers H F and DeLeo F R 2009 *Nat Rev Microbiol* 7 9
[8] Burgees DS and Hall RG 2004 *Diagn Microb Infect Dis* 49
[9] Williams ST *et al* 1989 Genus Streptomyces *Berger's Manual of Systematic Bacteriology* ed Williams ST *et al* (Baltimore: Williams & Wilkins) vol 4 pp. 2452-2492
[10] Shirling EB and Gottlieb D 1966 *Int J Syst Evol Microbiol* 16 3
[11] Pridham TG and Gottlieb D 1948 *J Bacteriol* 56 1
[12] Augustine SK, Bhavsar SP and Kapadnis BP 2005 *Indian J Med Res.* 121 3
[13] Moreira R A, Cavalcanti M T H, Duarte H S, Tambourgi E B, de Melo EH M Silva V L Porto AL F and de Lima F J L 2001 *Brazilian J of Microbial* 32 10
[14] Departemen Kesehatan Republik Indonesia 1995 *Farmakope Indonesia 4th Edition*, Jakarta, Departemen Kesehatan Republik Indonesia
[15] Afifi M M, Atta H M, and Bayoumi R A 2014 *Res J Microbiol* 9 1
[16] Xie Y, Ma J, Qin X, Li Q and Ju J 2017 *Microb Cell Fact* 16 177
[17] Bonfliiglio G and Fumetti P M 2001 *Expert Opinion on Investigational Drugs* 10 2
[18] Poolman JT and Anderson AS 2018 *Expert Rev Vaccines* 177
[19] WHO 2014 Antimicrobial resistance: global report on surveillance (Geneva: WHO Press) pp. X-XI, 12-15, 19-21
Antimicrobial activity of Streptomyces griseoviridis K10 against ESBL Escherichia coli, MRSA, and other pathogenic microorganisms

ORIGINALITY REPORT

SIMILARITY INDEX 9%
INTERNET SOURCES 7%
PUBLICATIONS 7%
STUDENT PAPERS 0%

PRIMARY SOURCES

1. Gaspar-Marques, C.. "Abietanes from Plectranthus grandidentatus and P. hereroensis against methicillin- and vancomycin-resistant bacteria", Phytomedicine, 20060313

2. "Biology and Biotechnology of Actinobacteria", Springer Science and Business Media LLC, 2017

3. hdl.handle.net

4. www.elsevier.es

5. www.ijpsonline.com

6. greenpharmacy.info
Rabah Forar Laidi. "A new actinomycete strain SK4-6 producing secondary metabolite effective against methicillin-resistant Staphylococcus aureus", World Journal of Microbiology and Biotechnology, 10/2008
Antimicrobial activity of Streptomyces griseoviridis K10 against ESBL Escherichia coli, MRSA, and other pathogenic microorganisms

FINAL GRADE

/0

GENERAL COMMENTS

Instructor